Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction
Open Access
- 8 May 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (8) , 2126-2130
- https://doi.org/10.1093/humrep/del119
Abstract
BACKGROUND: A recent prospective randomized study from our group compared GnRH agonist (0.5 mg buserelin) and hCG (10 000 IU) for triggering of ovulation following a flexible antagonist protocol. The agonist group showed a poor reproductive outcome despite luteal phase support with progesterone and estradiol (E2). In the present prospective observational study, the health status of follicles from the above study was monitored by analysing the hormonal content of frozen/thawed follicular fluid samples. The aim was to test whether the poor reproductive outcome could be related to a defective pre-ovulatory follicular maturation resulting in oocytes with a compromised developmental competence. METHODS: Hormone concentrations were measured in two individual follicular fluid samples from each of 32 women receiving buserelin and 37 receiving hCG, thus representing a subset of the follicles retrieved. RESULTS: Follicular fluid levels of LH in the agonist group as compared with the hCG group was 11.1 ± 0.5 versus 3.6 ± 0.3 IU/l (mean ± SEM; P < 0.001); FSH, 6.3 ± 0.6 versus 3.3 ± 0.2 IU/l (P < 0.001); hCG, not determined versus 139±8 IU/l; E2, 1.9 ± 0.2 versus 1.8 ± 0.2 µmol/l (P > 0.10); progesterone, 70 ± 4 versus 93 ± 6 µmol/l (P < 0.001); inhibin-A, 36.9 ± 3.1 versus 37.1 ± 2.5 ng/ml (P > 0.10) and inhibin-B, 35.6 ± 2.8 versus 40.1 ± 3.1 ng/ml (P > 0.10). Thus, pronounced hormonal differences exist in follicular fluid, and the collective concentration of all three gonadotropins and the follicular fluid concentration of progesterone were much higher in the group of women receiving hCG for ovulation induction. CONCLUSION: The study suggests that GnRH agonist results in proper pre-ovulatory follicular maturation, but the ovulatory signal – probably in synergy with the resulting pituitary down-regulation – is too low to support appropriate corpus luteum (CL) function.Keywords
This publication has 15 references indexed in Scilit:
- A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonistsHuman Reproduction, 2005
- GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized studyHuman Reproduction, 2005
- Nongonadal LH receptors, their involvement in female reproductive function and a new applicable approachThe Veterinary Journal, 2005
- Nonsupplemented Luteal Phase Characteristics after the Administration of Recombinant Human Chorionic Gonadotropin, Recombinant Luteinizing Hormone, or Gonadotropin-Releasing Hormone (GnRH) Agonist to Induce Final Oocyte Maturation inin VitroFertilization Patients after Ovarian Stimulation with Recombinant Follicle-Stimulating Hormone and GnRH Antagonist CotreatmentJournal of Clinical Endocrinology & Metabolism, 2003
- The Lutropin/Choriogonadotropin Receptor, A 2002 PerspectiveEndocrine Reviews, 2002
- Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation forin VitroFertilizationJournal of Clinical Endocrinology & Metabolism, 2002
- 6 Gonadotropin-lnduced Resumption of Oocyte Meiosis and Meiosis-Activating SterolsPublished by Elsevier ,1998
- Use of Gonadotropin-Releasing Hormone Agonist to Trigger Follicular Maturation for in Vitro Fertilization*Journal of Clinical Endocrinology & Metabolism, 1990
- Ovulation induction using “pure” follicle-stimulating hormone in monkeysFertility and Sterility, 1984
- Hormonal Dynamics at Midcycle: A Reevaluation*Journal of Clinical Endocrinology & Metabolism, 1983